Johnson & Johnson Price to Free Cash Flow Ratio 2012-2026 | JNJ
Historical price to free cash flow ratio values for Johnson & Johnson (JNJ) since 2012.
| Johnson & Johnson Price to Free Cash Flow Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM FCF per Share | Price to FCF Ratio |
| 2026-06-15 | 235.66 | 28.04 | |
| 2025-12-31 | 204.66 | $8.40 | 24.35 |
| 2025-09-30 | 182.21 | $8.25 | 22.07 |
| 2025-06-30 | 149.01 | $7.82 | 19.07 |
| 2025-03-31 | 160.41 | $8.70 | 18.45 |
| 2024-12-31 | 138.77 | $8.45 | 16.43 |
| 2024-09-30 | 154.27 | $8.69 | 17.74 |
| 2024-06-30 | 138.09 | $8.48 | 16.28 |
| 2024-03-31 | 148.25 | $7.59 | 19.53 |
| 2023-12-31 | 145.79 | $7.27 | 20.06 |
| 2023-09-30 | 143.72 | $6.28 | 22.89 |
| 2023-06-30 | 151.63 | $5.63 | 26.95 |
| 2023-03-31 | 140.93 | $6.23 | 22.62 |
| 2022-12-31 | 159.47 | $6.65 | 23.96 |
| 2022-09-30 | 146.52 | $6.80 | 21.55 |
| 2022-06-30 | 158.15 | $7.60 | 20.80 |
| 2022-03-31 | 156.90 | $7.52 | 20.88 |
| 2021-12-31 | 150.48 | $7.65 | 19.66 |
| 2021-09-30 | 141.13 | $8.72 | 16.18 |
| 2021-06-30 | 143.11 | $8.77 | 16.32 |
| 2021-03-31 | 141.89 | $8.14 | 17.43 |
| 2020-12-31 | 135.03 | $7.67 | 17.60 |
| 2020-09-30 | 126.86 | $6.91 | 18.36 |
| 2020-06-30 | 119.04 | $6.65 | 17.90 |
| 2020-03-31 | 110.23 | $8.50 | 12.96 |
| 2019-12-31 | 121.84 | $8.64 | 14.11 |
| 2019-09-30 | 107.33 | $9.35 | 11.48 |
| 2019-06-30 | 114.68 | $8.74 | 13.12 |
| 2019-03-31 | 114.32 | $8.04 | 14.21 |
| 2018-12-31 | 104.84 | $7.97 | 13.16 |
| 2018-09-30 | 111.54 | $7.48 | 14.92 |
| 2018-06-30 | 97.30 | $7.70 | 12.64 |
| 2018-03-31 | 102.01 | $7.36 | 13.85 |
| 2017-12-31 | 110.51 | $7.14 | 15.47 |
| 2017-09-30 | 102.20 | $7.11 | 14.37 |
| 2017-06-30 | 103.34 | $6.62 | 15.60 |
| 2017-03-31 | 96.65 | $6.33 | 15.27 |
| 2016-12-31 | 88.82 | $6.03 | 14.74 |
| 2016-09-30 | 90.44 | $5.86 | 15.42 |
| 2016-06-30 | 92.25 | $6.19 | 14.90 |
| 2016-03-31 | 81.71 | $6.66 | 12.28 |
| 2015-12-31 | 77.01 | $6.96 | 11.07 |
| 2015-09-30 | 69.47 | $6.13 | 11.34 |
| 2015-06-30 | 71.98 | $6.80 | 10.58 |
| 2015-03-31 | 73.76 | $6.56 | 11.25 |
| 2014-12-31 | 76.14 | $6.85 | 11.11 |
| 2014-09-30 | 77.11 | $6.76 | 11.42 |
| 2014-06-30 | 75.18 | $5.83 | 12.91 |
| 2014-03-31 | 70.10 | $5.49 | 12.76 |
| 2013-12-31 | 64.89 | $4.96 | 13.08 |
| 2013-09-30 | 60.99 | $4.94 | 12.36 |
| 2013-06-30 | 59.96 | $4.71 | 12.72 |
| 2013-03-31 | 56.51 | $4.64 | 12.18 |
| 2012-12-31 | 48.20 | $4.97 | 9.70 |
| 2012-09-30 | 46.97 | $5.02 | 9.36 |
| 2012-06-30 | 45.63 | $5.05 | 9.03 |
| 2012-03-31 | 44.12 | $4.83 | 9.14 |
| 2011-12-31 | 43.48 | $4.59 | 9.47 |
| 2011-09-30 | 41.84 | $4.62 | 9.05 |
| 2011-06-30 | 43.32 | $4.71 | 9.20 |
| 2011-03-31 | 38.25 | $4.72 | 8.11 |
| 2010-12-31 | 39.57 | $5.21 | 7.60 |
| 2010-09-30 | 39.30 | $5.76 | 6.82 |
| 2010-06-30 | 37.11 | $5.69 | 6.52 |
| 2010-03-31 | 40.60 | $5.50 | 7.38 |
| 2009-12-31 | 39.80 | $5.15 | 7.73 |
| 2009-09-30 | 37.33 | $4.77 | 7.83 |
| 2009-06-30 | 34.55 | $4.60 | 7.51 |
| 2009-03-31 | 31.71 | $4.36 | 7.27 |
| 2008-12-31 | 35.77 | $4.48 | 7.99 |
| 2008-09-30 | 41.08 | $4.28 | 9.60 |
| 2008-06-30 | 37.91 | $4.03 | 9.40 |
| 2008-03-31 | 37.95 | $4.05 | 9.38 |
| 2007-12-31 | 38.76 | $4.31 | 9.00 |
| 2007-09-30 | 37.95 | $4.49 | 8.46 |
| 2007-06-30 | 35.35 | $4.49 | 7.87 |
| 2007-03-31 | 34.35 | $4.30 | 7.98 |
| 2006-12-31 | 37.41 | $4.08 | 9.16 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |